Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Canopy FGF signaling regulator 1 (CNPY1)
- Target
- CNPY1
- Molecular classification
- Protein of unknown detailed function (classified as “protein canopy homolog”), Member of the canopy (CNPY) protein family, Domain of unknown function DUF3456
01
Overview
Canopy FGF signaling regulator 1 (CNPY1) is a conserved intracellular protein involved in embryonic developmental processes. It acts as a positive regulator of FGF signaling by assisting in the maturation of the FGFR1 receptor in the endoplasmic reticulum, thus amplifying FGF signals needed for cell clustering, adhesion, and laterality patterning in the early embryo. Its biological importance is demonstrated in zebrafish, where loss of CNPY1 causes clustering defects in forerunner cells and abnormal ciliogenesis, leading to failures in left-right (LR) body axis patterning and cardiac development. The protein is detected in several tissues and has low tissue specificity. CNPY1 serves as a molecular marker for certain cancers but is not currently pursued as a drug target or biomarker in therapeutics.
- Other names
- Protein canopy homolog 1Canopy 1 homologCNPY1Canopy FGF signaling regulator 1
02
Mechanism of action
Not applicable; CNPY1 is not a drug target and there is no mechanism described for drug interaction
03
Biological functions
Regulation of fibroblast growth factor receptor (FGFR) signalingModulates FGF signal amplification during developmentControls cell clustering and cell adhesion via cadherin1 (cdh1) inductionRequired for ciliogenesis and proper left-right (LR) patterning in embryonic development, notably in zebrafishInvolved in Kupffer's vesicle development, regionalization
04
Disease associations
Potential marker in cancer: unfavorable in renal cancer, favorable in pancreatic cancerAssociated with Heimler Syndrome 2 and Coenzyme Q10 Deficiency, Primary, 2 (by gene linkage, not direct evidence of pathogenesis)Implicated in developmental disorders due to effects on cell movement/clustering in embryos
05
Safety considerations
No safety concerns documented, as CNPY1 is not a therapeutic target
06
Biomarkers
Suggested as a marker in renal and pancreatic cancer (expression/favorable/unfavorable prognostic value)No established companion diagnostics or biomarkers in clinical use
Beyond the preview
Go deeper on Canopy FGF signaling regulator 1 (CNPY1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Canopy FGF signaling regulator 1 (CNPY1).